Trial Profile
European Myeloma Network Sequential Phase I / Phase II Trial on RIC Allogeneic Transplantation: an Optimized Program for High Risk Relapsed Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Lenalidomide (Primary)
- Indications Graft-versus-host disease; Haematological malignancies; Multiple myeloma
- Focus Adverse reactions
- Acronyms EMN-alloRIC; EMN-ALLORIC2010
- 21 Jun 2020 Updated results (n=24) assessing toxicity and efficacy of a reduced intensity conditioning regimens with bortezomib and post-transplant maintenance with bortezomib and lenalidomide in high risk multiple myeloma patients, presented at the 25th Congress of the European Haematology Association.
- 24 Sep 2019 Results assessing safety and efficacy of bortezomib as part of both the conditioning regimen and the graft-versus-host disease prophylaxis published in the Bone Marrow Transplantation
- 05 Jul 2017 Status changed from recruiting to completed.